The RAPID - PE Study: Treatment for Pulmonary Embolism
This study is testing a new way to treat pulmonary embolism (PE), which is a blood clot in the lung. It uses a device called the Bashir™ Endovascular Catheter along with a medicine called r-tPA. The catheter helps deliver r-tPA directly to the blood clot. You might be able to join if you have PE symptoms for 15 days or less, have a blood clot in a major lung artery, and are diagnosed with intermediate risk PE. Researchers will measure if this treatment prevents death or a worsening of your condition (hemodynamic decompensation or collapse) from the procedure through 7 days after. The study aims to enroll 500 participants, but its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 500 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed from the procedure through 7-day follow-up to check for death or hemodynamic decompensation.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
The RAPID - PE Study: RESCUE Advanced Protocol for the Treatment of Pulmonary Embolism
At a glance
Conditions
NCT06433011
Where you'd take part
This study runs at 23 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Beth Israel Deaconess Medical Center
Boston, Massachusettsstudy coordinator listed
Recruiting
Boston Medical Center
Boston, Massachusettsstudy coordinator listed
Recruiting
Carondelet St. Joseph's Hospital
Tuscon, Arizonastudy coordinator listed
Recruiting
Charleston Area Medical Center
Charleston, West Virginiastudy coordinator listed
Recruiting
Community Health
Indianapolis, Indianastudy coordinator listed
Recruiting
Cooper Health
Camden, New Jerseystudy coordinator listed
Recruiting
Dartmouth Hitchcock
Lebanon, New Hampshirestudy coordinator listed
Recruiting
Emory University
Atlanta, Georgiastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Karen Stephens · STUDY_DIRECTOR · Thrombolex, Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Efficacy: Death from any cause or hemodynamic decompensation (or collapse)Procedure through 7-day follow-up
Observe death from any cause or hemodynamic decompensation (or collapse) through 7-day follow-up, defined as need for cardiopulmonary resuscitation; or 1. SBP \< 90 mmHg for at least 15 minutes; or 2. drop in SBP by at least 40 mmHg for at least 15 minutes with signs of end-organ hypoperfusion (cold extremities or low urinary output \< 30 mL/h or mental confusion); or 3. need for catecholamine administration to maintain adequate organ perfusion and a SBP \> 90 mmHg (including dopamine at the rate of \> 5 micrograms / kg per minute).